由于严重或危急的COVID-19住院的间歇性肺病患者的死亡率
Ana Karem S Pruneda1, José Omar Barreto-Rodríguez1, Moises Selman1
1Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Calzada de Tlalpan 4502, Col. Sección XVI, 14080, Mexico, Tlalpan, Mexico.
BMC pulmonary medicine
|October 12, 2023
概括
与以前没有肺部疾病的患者相比,患有间歇性肺部疾病 (ILD) 和危急COVID-19的患者的死亡率明显更高. 较高的BMI和并发症与COVID-19的ILD患者的不生存有关.
科学领域:
- 肺部病理学 肺部病理学
- 传染性疾病 传染性疾病
- 关键护理医学 关键护理医学
背景情况:
- 严重的COVID-19对先前存在间歇性肺病 (ILD) 的患者的影响尚不清楚.
- 这项研究旨在描述住院患有严重COVID-19的ILD患者,并比较他们的死亡率与对照组.
研究的目的:
- 为了描述住院的ILD患者的临床特征的基线临床特征,ILD患者患有严重的COVID-19.
- 为了比较ILD患者和与COVID-19相匹配的对照组之间的死亡率,但没有先前的肺病.
主要方法:
- 一项病例对照研究,将41名患有严重COVID-19的ILD患者与82名匹配的对照人群 (COVID-19,没有先前的肺病) 进行比较.
- 评估社会人口统计学变量,入院时的实验室测试和临床结果.
- 在ILD队列中对非幸存者与幸存者的子分析.
主要成果:
- 患有COVID-19的ILD组的死亡率更高 (63%对33%,p=0.007).
- 在ILD患者中,女性占主导地位,白细胞和中性粒细胞数量较低.
- 在ILD组中没有幸存者有更高的BMI和更短的住院时间和症状持续时间.
结论:
- 间歇性肺病显著增加了临界COVID-19患者的死亡风险.
- 较高的BMI和并发症与严重COVID-19的ILD患者的较差结果有关.
相关概念视频
01:30Pneumonia III: Complications and Assessment
243
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
243
01:28Pneumonia IV: Management
350
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
350
01:29Pulmonary Tuberculosis I
247
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
247
01:30Pneumonia I: Introduction
250
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
250
01:21Acute Respiratory Failure-II
250
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
250
01:29Acute Respiratory Failure-V
144
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
144